Cryolife Inc (NYSE:CRY) CEO James P. Mackin sold 150,000 shares of the firm’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $32.16, for a total value of $4,824,000.00. Following the completion of the sale, the chief executive officer now owns 380,970 shares of the company’s stock, valued at $12,251,995.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of CRY opened at $32.25 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.97 and a quick ratio of 3.63. The stock has a market capitalization of $1.21 billion, a PE ratio of 80.63 and a beta of 0.73. Cryolife Inc has a one year low of $16.80 and a one year high of $34.15.
Cryolife (NYSE:CRY) last issued its earnings results on Monday, August 6th. The medical equipment provider reported $0.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The company had revenue of $68.50 million during the quarter, compared to the consensus estimate of $64.08 million. Cryolife had a positive return on equity of 4.28% and a negative net margin of 2.34%. The firm’s revenue for the quarter was up 43.2% compared to the same quarter last year. During the same period last year, the business posted $0.12 EPS. sell-side analysts forecast that Cryolife Inc will post 0.31 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its position in Cryolife by 15.9% in the 2nd quarter. Victory Capital Management Inc. now owns 14,596 shares of the medical equipment provider’s stock valued at $406,000 after acquiring an additional 2,002 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Cryolife by 117.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,305 shares of the medical equipment provider’s stock valued at $176,000 after acquiring an additional 3,400 shares in the last quarter. New York State Common Retirement Fund lifted its position in Cryolife by 13.0% in the 1st quarter. New York State Common Retirement Fund now owns 36,500 shares of the medical equipment provider’s stock valued at $732,000 after acquiring an additional 4,200 shares in the last quarter. Swiss National Bank lifted its position in Cryolife by 8.1% in the 2nd quarter. Swiss National Bank now owns 58,500 shares of the medical equipment provider’s stock valued at $1,629,000 after acquiring an additional 4,400 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Cryolife by 3.7% in the 2nd quarter. Bank of America Corp DE now owns 127,412 shares of the medical equipment provider’s stock valued at $3,548,000 after acquiring an additional 4,517 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently commented on CRY. Canaccord Genuity raised their target price on Cryolife from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Zacks Investment Research downgraded Cryolife from a “buy” rating to a “hold” rating in a research note on Tuesday, May 29th. ValuEngine upgraded Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 23rd. Finally, Northland Securities restated a “buy” rating and issued a $32.00 target price on shares of Cryolife in a research note on Tuesday, August 7th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $32.75.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Recommended Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.